MiNK Therapeutics (INKT) Enterprise Value (2020 - 2026)
MiNK Therapeutics (INKT) posted Enterprise Value of -$9.5 million for Q1 2026, up 28.7% sequentially from -$13.4 million in Q4 2025, and down 197.68% YoY from $9.8 million in Q1 2025.
MiNK Therapeutics (INKT) Enterprise Value (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$9.5 million in Q1 2026.
- Quarterly Enterprise Value fell 197.68% year-over-year to -$9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.5 million (down 197.68% YoY) and the FY2025 annual result came in at -$13.4 million, down 191.9% from the prior year.
- Enterprise Value grew to -$9.5 million in Q1 2026 per INKT's latest filing, from -$13.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.7 million in Q2 2025 and troughed at -$34.7 million in Q1 2022.
- A 5-year average of -$12.2 million and a median of -$9.5 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 2848.15% in 2022, then soared 82.85% in 2023.
- Over 5 years, Enterprise Value stood at -$19.6 million in 2022, then jumped by 82.85% to -$3.4 million in 2023, then tumbled by 35.93% to -$4.6 million in 2024, then tumbled by 191.9% to -$13.4 million in 2025, then climbed by 28.7% to -$9.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$9.5 million, -$13.4 million, and -$9.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | -8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.81 Mn |
| Mar 31, 2026 | -9.53 Mn |
| Dec 31, 2025 | -13.36 Mn |
| Sep 30, 2025 | -9.50 Mn |
| Jun 30, 2025 | -1.68 Mn |
| Mar 31, 2025 | -3.20 Mn |
| Dec 31, 2024 | -4.58 Mn |
| Sep 30, 2024 | -6.33 Mn |
| Jun 30, 2024 | -9.30 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | -3.37 Mn |
| Sep 30, 2023 | -6.40 Mn |
| Jun 30, 2023 | -10.60 Mn |
| Mar 31, 2023 | -14.90 Mn |
| Dec 31, 2022 | -19.64 Mn |
| Sep 30, 2022 | -24.16 Mn |
| Jun 30, 2022 | -29.80 Mn |
| Mar 31, 2022 | -34.69 Mn |
| Dec 31, 2021 | -38.89 Mn |
| Sep 30, 2021 | -819,450.00 |